Dear NCPA member:

As you know, NCPA is suing the Department of Health and Human Services to end pharmacy DIR fees. Fixing pharmacy DIR has been NCPA's top priority since 2014, and we came very close to succeeding in 2019, only to have the effort blocked by the White House at the last minute.

Enough is enough.


What we're trying to do here is put an end to HHS regulations that allow PBMs to impose pharmacy direct and indirect remuneration (DIR) fees that are driving small business neighborhood pharmacies out of business. Our case, NCPA v. Azar, was filed in U.S. District Court for the District of Columbia. The lawsuit alleges that the fees are without reasonable transparency, and they conceal from patients and taxpayers the true cost of prescription drugs.


On Thursday, Jan. 28, we invite you to join NCPA for a webinar, NCPA v. Azar: The Fight to End DIR, that will review our strong legal case against DIR fees. The webinar is at 8 p.m. ET. Register here.

We also ask you to support the fight by contributing to NCPA's Legislative/Legal Defense Fund as we pursue this fight on behalf of our members and the more than 21,000 community pharmacies we represent. Please give online at or text LDF to (703) 783-9397 to donate whatever you can give so that NCPA can keep fighting for you.


To unsubscribe from promotional emails and surveys but continue to receive important updates about community pharmacy issues, click here to manage your subscription preferences.

To unsubscribe from all NCPA emails, including alerts on developments impacting community pharmacies, click here.